Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of levodopa methyl ester hydrochloride in the treatment of periprosthetic osteolysis

A technology of levodopa methyl ester hydrochloride and periprosthetic bone, which is applied in the direction of drug combination and bone diseases, can solve the problem that there is no research on the relationship between periprosthetic osteolysis and so on, so as to inhibit the activation of osteoclasts and reduce inflammation The effect of the reaction

Inactive Publication Date: 2016-06-08
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is currently no research on the relationship between LDME and periprosthetic osteolysis after joint replacement, from which the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of levodopa methyl ester hydrochloride in the treatment of periprosthetic osteolysis
  • Pharmaceutical use of levodopa methyl ester hydrochloride in the treatment of periprosthetic osteolysis
  • Pharmaceutical use of levodopa methyl ester hydrochloride in the treatment of periprosthetic osteolysis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] 1. Materials and methods

[0025] 1. Materials

[0026] 1.1 Reagents and experimental equipment

[0027] 1.1.1 Main Drugs and Reagents

[0028]Levodopa methyl ester hydrochloride (LDME), TRAP staining kit, purchased from Sigma, the United States; paraformaldehyde, PBS, DAB chromogen, hematoxylin, eosin, absolute ethanol, distilled water, 10% chloral hydrate. Titanium particles were purchased from Johnson Mattheychemicals (catalog#00681; WardHill, Massachusetts); RANKL, OPG, TNF-α, IL-1β enzyme-linked immunosorbent assay kits were purchased from Biosource, the United States;

[0029] 1.1.2 Main instruments

[0030] Micro-CT (SkyScan1176, Belgium), paraffin slicer (Leica2135, Germany), slicer (Leica1120, Germany), paraffin embedding machine (BMJ-Ⅱ, China, Changzhou), Axiovert40C optical microscope (Zeiss, Germany), Microplate reader (Biotec, USA), a set of surgical instruments, etc.

[0031] 1.2 Experimental animals

[0032] Eighty healthy C57BL / J6 mice, male, weigh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses the use of levodopa methyl ester hydrochloride (LDME) in preparing a pharmaceutical composition for treating periprosthetic osteolysis. The chemical structural formula of levodopa methyl ester hydrochloride is as follows: . The pharmaceutical use of levodopa methyl ester (LDME) in the treatment of PPO after TJA provided by the present invention provides a new approach for preventing and treating periprosthetic osteolysis.

Description

technical field [0001] The invention belongs to the technical field of new uses of medicines, and relates to the medicinal use of levodopa methyl hydrochloride, in particular to the medicinal use of levodopa methyl hydrochloride in treating periprosthetic osteolysis. Background technique [0002] Peri-prosthetic osteolysis (PPO) is an important complication of total joint arthroplasty (TJA) and an important factor limiting the service life of artificial prosthesis. Studies have reported that after 10-20 years of prosthesis replacement, 10%-15% of artificial joints will fail, and more than 66% of hip revisions and nearly 50% of knee revisions are caused by PPO. It is known that the biological response caused by the long-term wear of the artificial prosthesis caused by tiny particles is the main cause of PPO, but the specific mechanism of PPO is still unclear, and the curative effect of various non-surgical treatments is not significant. Perform revision surgery. Since the c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61P19/08
Inventor 耿德春杨惠林徐耀增朱雪松毛海青
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com